Compare EPR Properties (EPR) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Mesoblast Limited — how do they compare? EPR Properties trades at $61.2 (market cap $4.58B), while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: EPR Properties is far larger — about 2.1× Mesoblast Limited's market cap, and EPR Properties pays a 6.22% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| EPR | MESO | |
|---|---|---|
Market Cap | $4.58B | $2.21B |
Sector | Real Estate | Technology |
52-Week High | $64.32 | $20.96 |
52-Week Low | $48.71 | $12.88 |
Enterprise Value | $8.09B | $2.21B |
Dividend Yield | 6.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties (EPR) trades at $61.41, up 1.67% in the last session, with a bearish technical signal despite strong Q2 2026 FFO beating estimates. The company reported revenue growth to $699 million in 2026, though net income dipped to $263 million, and maintains a high gross margin of 91.41%. Recent news highlights dividend declarations and a new $1.6 billion credit facility, supporting its experiential real estate focus.
Outlook is mixed: analyst consensus favors 'Hold' with a $65.30 price target, indicating modest upside, but technical indicators and a slight earnings miss in Q1 2026 pose risks. Opportunities include dividend growth and portfolio diversification, while risks involve investing cash flow volatility and sector competition.
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
